CRISPR Therapeutics AG (CRSP) Cash from Investing Activities (2015 - 2026)

CRISPR Therapeutics AG has disclosed Cash from Investing Activities across 12 years of filings, most recently posting -$55.7 million for Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 179.54% year-over-year to -$55.7 million; the TTM figure through Jun 2026 stood at -$548.4 million (down 9774.49% YoY), while the FY2025 annual figure was -$31.8 million, up 88.66% from the prior year.
• Cash from Investing Activities came in at -$55.7 million for Q2 2026 at CRISPR Therapeutics AG, up from -$410.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $216.9 million in Q2 2023 to a low of -$410.7 million in Q1 2026.
• Average Cash from Investing Activities over 5 years is -$36.8 million, with a median of -$55.9 million recorded in 2022.
• Year-over-year, Cash from Investing Activities surged 486.87% in 2023 and plunged 1979.19% in 2026.
• Over 5 years, Cash from Investing Activities stood at -$175.5 million in 2022, then jumped by 53.6% to -$81.5 million in 2023, then surged by 229.93% to $105.8 million in 2024, then plunged by 64.85% to $37.2 million in 2025, then tumbled by 249.62% to -$55.7 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$55.7 million in Q2 2026, -$410.7 million in Q1 2026, and $37.2 million in Q4 2025.